180 related articles for article (PubMed ID: 17266524)
1. Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6.
de Graaf C; Oostenbrink C; Keizers PH; van Vugt-Lussenburg BM; van Waterschoot RA; Tschirret-Guth RA; Commandeur JN; Vermeulen NP
Curr Drug Metab; 2007 Jan; 8(1):59-77. PubMed ID: 17266524
[TBL] [Abstract][Full Text] [Related]
2. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
[TBL] [Abstract][Full Text] [Related]
3. Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.
Unwalla RJ; Cross JB; Salaniwal S; Shilling AD; Leung L; Kao J; Humblet C
J Comput Aided Mol Des; 2010 Mar; 24(3):237-56. PubMed ID: 20361239
[TBL] [Abstract][Full Text] [Related]
4. Analysis of CYP2D6 substrate interactions by computational methods.
Ito Y; Kondo H; Goldfarb PS; Lewis DF
J Mol Graph Model; 2008 Feb; 26(6):947-56. PubMed ID: 17764997
[TBL] [Abstract][Full Text] [Related]
5. Prediction of drug metabolism: the case of cytochrome P450 2D6.
Vermeulen NP
Curr Top Med Chem; 2003; 3(11):1227-39. PubMed ID: 12769702
[TBL] [Abstract][Full Text] [Related]
6. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B; Yang LP; Zhang XZ; Huang SQ; Bartlam M; Zhou SF
Drug Metab Rev; 2009; 41(4):573-643. PubMed ID: 19645588
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening.
Mo SL; Liu WF; Li CG; Zhou ZW; Luo HB; Chew H; Liang J; Zhou SF
Curr Pharm Biotechnol; 2012 Jul; 13(9):1640-704. PubMed ID: 22039821
[TBL] [Abstract][Full Text] [Related]
8. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism.
Lewis DF; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1997 Apr; 27(4):319-39. PubMed ID: 9149373
[TBL] [Abstract][Full Text] [Related]
9. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144
[TBL] [Abstract][Full Text] [Related]
10. A molecular model of CYP2D6 constructed by homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactions.
Lewis DF; Dickins M; Lake BG; Goldfarb PS
Drug Metabol Drug Interact; 2003; 19(3):189-210. PubMed ID: 14682610
[TBL] [Abstract][Full Text] [Related]
11. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
[TBL] [Abstract][Full Text] [Related]
12. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.
Guengerich FP; Miller GP; Hanna IH; Martin MV; Léger S; Black C; Chauret N; Silva JM; Trimble LA; Yergey JA; Nicoll-Griffith DA
Biochemistry; 2002 Sep; 41(36):11025-34. PubMed ID: 12206675
[TBL] [Abstract][Full Text] [Related]
13. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding.
McLaughlin LA; Paine MJ; Kemp CA; Maréchal JD; Flanagan JU; Ward CJ; Sutcliffe MJ; Roberts GC; Wolf CR
J Biol Chem; 2005 Nov; 280(46):38617-24. PubMed ID: 16162505
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of N-substituted 7-methoxy-4-(aminomethyl) -coumarins by cytochrome P450 2D6 mutants and the indication of additional substrate interaction points.
Keizers PH; Van Dijk BR; De Graaf C; Van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN
Xenobiotica; 2006 Sep; 36(9):763-71. PubMed ID: 16971342
[TBL] [Abstract][Full Text] [Related]
15. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
Kemp CA; Flanagan JU; van Eldik AJ; Maréchal JD; Wolf CR; Roberts GC; Paine MJ; Sutcliffe MJ
J Med Chem; 2004 Oct; 47(22):5340-6. PubMed ID: 15481972
[TBL] [Abstract][Full Text] [Related]
16. Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3.
Stjernschantz E; van Vugt-Lussenburg BM; Bonifacio A; de Beer SB; van der Zwan G; Gooijer C; Commandeur JN; Vermeulen NP; Oostenbrink C
Proteins; 2008 Apr; 71(1):336-52. PubMed ID: 17957765
[TBL] [Abstract][Full Text] [Related]
17. Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6.
Kirton SB; Kemp CA; Tomkinson NP; St-Gallay S; Sutcliffe MJ
Proteins; 2002 Nov; 49(2):216-31. PubMed ID: 12211002
[TBL] [Abstract][Full Text] [Related]
18. Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
Venhorst J; ter Laak AM; Commandeur JN; Funae Y; Hiroi T; Vermeulen NP
J Med Chem; 2003 Jan; 46(1):74-86. PubMed ID: 12502361
[TBL] [Abstract][Full Text] [Related]
19. Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity.
Smith G; Modi S; Pillai I; Lian LY; Sutcliffe MJ; Pritchard MP; Friedberg T; Roberts GC; Wolf CR
Biochem J; 1998 May; 331 ( Pt 3)(Pt 3):783-92. PubMed ID: 9560305
[TBL] [Abstract][Full Text] [Related]
20. Double site saturation mutagenesis of the human cytochrome P450 2D6 results in regioselective steroid hydroxylation.
Geier M; Braun A; Fladischer P; Stepniak P; Rudroff F; Hametner C; Mihovilovic MD; Glieder A
FEBS J; 2013 Jul; 280(13):3094-108. PubMed ID: 23552177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
